Chondrocalcinosis – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:17:55 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Chondrocalcinosis – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of tocilizumab compared to placebo in patients with chronic chondrocalcinosis who did not respond to standard treatments https://clinicaltrials.eu/trial/study-of-tocilizumab-compared-to-placebo-in-patients-with-chronic-chondrocalcinosis-who-did-not-respond-to-standard-treatments/ Wed, 29 Apr 2026 15:06:23 +0000 https://clinicaltrials.eu/trial/study-of-tocilizumab-compared-to-placebo-in-patients-with-chronic-chondrocalcinosis-who-did-not-respond-to-standard-treatments/ This clinical trial focuses on treating chondrocalcinosis, a condition where calcium crystals build up in joint cartilage causing inflammation and pain. The study evaluates the effectiveness of tocilizumab, a medication given through intravenous infusion, in patients whose condition has not improved with standard treatments.

The study compares tocilizumab to placebo in patients with chronic inflammatory joint pain. The medication works by blocking a protein called IL-6 that is involved in inflammation. Participants will receive either tocilizumab or a sodium chloride solution (placebo) through an infusion into their vein once a month for three months.

During the study, patients will be monitored for changes in their pain levels and joint inflammation. The total duration of observation will be six months, with regular check-ups to assess how well the treatment is working and to monitor for any side effects. The medication being tested (tocilizumab) is available under different brand names including RoActemra, Tofidence, Avtozma, and Tyenne.

]]> Study on Baricitinib for Patients with Calcium Pyrophosphate Deposition Disease (CPPD) Using Methotrexate Sodium and Drug Combination https://clinicaltrials.eu/trial/study-on-baricitinib-for-patients-with-calcium-pyrophosphate-deposition-disease-cppd-using-methotrexate-sodium-and-drug-combination/ Wed, 29 Apr 2026 14:59:21 +0000 https://clinicaltrials.eu/trial/study-on-baricitinib-for-patients-with-calcium-pyrophosphate-deposition-disease-cppd-using-methotrexate-sodium-and-drug-combination/ This clinical trial is focused on studying the effects of the medication Baricitinib on a condition known as Calcium Pyrophosphate Deposition Disease (CPPD). CPPD is a type of arthritis that causes joint pain and swelling due to the buildup of calcium crystals in the joints. The purpose of the study is to evaluate how Baricitinib affects inflammation in the joint lining, which is a common issue in people with CPPD.

Participants in the study will receive Baricitinib in the form of film-coated tablets. The study will also involve other medications, including Methotrexate Sodium, Colchicine, Tiemonium Methylsulphate, Calcium Folinate, Hydroxychloroquine Sulfate, and Lidocaine Hydrochloride Monohydrate. These medications are used for various purposes, such as reducing inflammation, managing pain, and supporting joint health. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of the treatments.

The study will last for a period of 24 weeks, during which participants will take the medication orally. Throughout the study, changes in joint inflammation and other health indicators will be monitored. The goal is to understand how Baricitinib and the other medications can help manage symptoms of CPPD and improve the quality of life for those affected by this condition.

]]>